BiotechTube

CAB-ROR2-ADC + PD-1 inhibitor

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Small Cell Lung Cancer

Conditions

Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer

Trial Timeline

Jun 27, 2018 → Dec 30, 2024

NCT ID
NCT03504488

About CAB-ROR2-ADC + PD-1 inhibitor

CAB-ROR2-ADC + PD-1 inhibitor is a phase 1/2 stage product being developed by BioAtla for Non Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03504488. Target conditions include Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03504488Phase 1/2Completed

Competing Products

20 competing products in Non Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
BBP-398 with nivolumabBridgeBio PharmaPhase 1
30
Pemetrexed + CarboplatinEli LillyPhase 3
77
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
SelpercatinibEli LillyPre-clinical
23
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3NanobiotixPhase 1/2
36
PemetrexedEli LillyPre-clinical
23
pemetrexed + erlotinibEli LillyPhase 2
52
LY3295668 ErbumineEli LillyPhase 1
33
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
69
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
69
pemetrexed + cisplatinEli LillyPhase 2
52
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
pemetrexed + docetaxelEli LillyPhase 3
77
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
52
PemCarbo + Pem onlyEli LillyPhase 3
77
TNG456 + abemaciclibEli LillyPhase 1/2
41
pemetrexed + cisplatinEli LillyPhase 1/2
41

Other Products from BioAtla

CAB-AXL-ADC + PD-1 inhibitorPhase 2
44
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabPhase 2
44
Durvalumab + BA3011 + BA3021 + ENB003 + ToripalimabPhase 2
44
CAB-AXL-ADC + PD-1 inhibitorPhase 1/2
33
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)Phase 1/2
33